news outSernova Retains FronTier Merchant Capital for North America Investor Relations and Marketing Sernova Engages IR and Marketing Firm as Anticipated Event-Driven Catalysts Approach LONDON, ONTARIO (Marketwire Tuesday August 15, 2017) Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a leading clinical stage regenerative medicine company, is pleased to announce that it has engaged FronTier Merchant Capital Group to provide North American investor relations (IR) and strategic marketing services to the financial community and media across North America with the goal to build shareholder value. Sernova President and CEO Dr. Philip Toleikis commented, "We are pleased to select FronTier Merchant Capital to work with us and serve as our North American investor relations advisors. FronTiers extensive expertise and experience with impactful media channels and reach into the investment community is expected to greatly enhance the scope and quality of our domestic and US investor relations programs through strategic messaging and investor outreach. Using its extensive network, comprised of financial industry professionals, active investors and marketing service providers, FronTier will help to effectively communicate Sernovas investment potential and corporate vision. With important anticipated catalysts such as near term initiation of a US clinical trial of its Cell Pouch technologies, expanding pharma collaborations, and subsequent expected upgrade of its US listing to a senior exchange, FronTier will assist the company by increasing market awareness through financial market communications, including facilitating in-person introductions for the company with institutional and retail brokers in Canada and throughout the United States, and through media distribution on national television, radio and multiple on-line channels. FronTier has offices in Toronto, Montreal and Calgary. Under the terms of the engagement, FronTier has been retained for a 12-month period at $80,000 per annum plus direct expenses. In other developments, Sernovas board of directors has approved an amendment to the companys Option Plan & Deferred Share Unit Plan (the Amended Plan) to increase the maximum number of Deferred Share Units (DSUs) issuable by an additional 660,222 DSUs to a maximum of 1,975,000 DSUs. Further to the Amended Plan, Sernova has granted 3,735,000 stock options to certain officers, employees and consultants of the company, each such option being exercisable into a common share at a price of $0.25 per share for a period of 10 years, and conditionally granted 900,000 DSUs to its board of directors. The DSU grants are subject to the company obtaining shareholder approval and TSX Venture Exchange approval.